Oragenics (OGEN) Stock Rose: Investor Confidence Boosted By Regulatory Green Light
On Friday, Oragenics, Inc. (NYSE: OGEN) received a significant boost in investor confidence following the regulatory approval for its lead drug candidate, ONP-002. This positive development propelled OGEN shares to a notable $1.40, marking a substantial increase of 29.63%. Successful Study Results for ONP-002 Oragenics (OGEN) announced that ONP-002, its principal therapeutic candidate, had finished […]
